Literature DB >> 19364332

Topical nepafenac for treatment of exudative age-related macular degeneration.

Teodosio Libondi, Jost B Jonas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364332     DOI: 10.1111/j.1755-3768.2008.01491.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  5 in total

1.  The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.

Authors:  Y Wang; V M Wang; C-C Chan
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

2.  The Effect of Topical Bromfenac on Intraretinal and Subretinal Fluid in Neovascular Age-Related Macular Degeneration.

Authors:  Solmaz Abdolrahimzadeh; Valeria Fameli; Federico Di Tizio; Federico Di Staso; Vito Fenicia; Gianluca Scuderi
Journal:  J Curr Ophthalmol       Date:  2020-04-30

3.  Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections.

Authors:  Eric Chen; Matthew S Benz; Richard H Fish; David M Brown; Tien P Wong; Rosa Y Kim; James C Major
Journal:  Clin Ophthalmol       Date:  2010-10-28

4.  Ophthalmic nepafenac use in the Netherlands and Denmark.

Authors:  Andrea V Margulis; Eline Houben; Jesper Hallas; Jetty A Overbeek; Anton Pottegård; Tobias Torp-Pedersen; Susana Perez-Gutthann; Alejandro Arana
Journal:  Acta Ophthalmol       Date:  2017-05-10       Impact factor: 3.761

5.  Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection.

Authors:  Tevfik Ogurel; Reyhan Ogurel; Fatma Ozkal; Yaşar Ölmez; Nurgül Örnek; Zafer Onaran
Journal:  Ther Adv Ophthalmol       Date:  2019-07-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.